Group 1: Company Overview and Strategy - The company focuses on mergers and acquisitions that align with its strategic development, aiming to enhance its supply chain, technology, market competitiveness, and product pipeline [2] - The company has established a comprehensive sales channel system, particularly in the outpatient market, which has become a new growth engine for performance [3] Group 2: Product Development and Market Potential - The company believes that the market for Loxoprofen Sodium Gel Patch in the outpatient sector has significant growth potential, supported by stable demand for topical patches in retail [4] - The company plans to continue investing in R&D to expand its product line and strengthen its brand "JiuYue" in the transdermal drug delivery field [3] Group 3: Competitive Positioning - Loxoprofen Sodium Gel Patch is a prescription drug effective for osteoarthritis and muscle pain, while the anti-inflammatory patch is an over-the-counter product with different ingredients and indications [5] - The company aims to leverage its complete supply chain to control costs and ensure product quality in response to competitive products gaining approval [2] Group 4: Financial Projections - For 2025, the company expects a revenue growth of 10-20% and a similar increase in net profit excluding non-recurring items [6] - The company warns that its operational plans and sales forecasts are subject to market conditions and other uncertainties, advising investors to remain aware of risks [7] Group 5: Marketing and Promotion Strategies - The company employs a multi-channel strategy for OTC promotion, integrating online and offline channels, and enhancing consumer experience through educational activities [7] - The brand "JiuYue" is positioned to meet diverse consumer needs through differentiated marketing and a varied product portfolio [7]

关于九典转 02 恢复转股的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 1、债券代码：123223 债券简称：九典转02 2、转股期限：2024年3月21日至2029年9月14日 3、暂停转股时间：2025年5月19日至2025年5月23日 4、恢复转股时间：2025年5月26日 特别提示： 湖南九典制药股份有限公司（以下简称"公司"）因实施2024年度权益分派， 根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》相关规定，自2025年5月19日至2025年5月23日九典转02暂停转股，具体 内容详见公司于巨潮资讯网刊登的《关于实施2024年度权益分派期间九典转02 暂停转股的公告》（公告编号：2025-037）。 根据相关规定，自2024年度权益分派股权登记日后的第一个交易日（即2025 年5月26日）起九 ...

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Lidocaine Gel Patch, indicating a significant regulatory approval for a new product aimed at treating postherpetic neuralgia [1] Group 1: Product Details - The drug is named Lidocaine Gel Patch, classified as a Class 3 chemical drug [1] - The formulation is a patch with dimensions of 14cm x 10cm, containing 14g of gel and 700mg of Lidocaine per patch [1] - The product is specifically indicated for alleviating pain associated with postherpetic neuralgia and is suitable for use on intact skin [1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-040 | 利多卡因凝胶贴膏由 Teikoku Seiyaku Co., Ltd.开发，1999 年 3 月首次在 美国上市，2024 年 5 月进口至中国上市。该贴膏属镇痛药，用于缓解带状疱疹 后神经痛，用于无破损皮肤。《带状疱疹后神经痛诊疗中国专家共识》明确将利 多卡因凝胶贴膏列为缓解带状疱疹后神经痛的首选外用药物，尤其适用于轻至中 度疼痛或无法耐受口服药物的患者。摩熵数据显示，利多卡因凝胶贴膏 2023 年 在全国医院销售（全终端）和全国药店零售的销售额分别为 10,783.35 万元和 536.49 万元。 2、剂型：贴膏剂 3、规格：每贴（14cm×10cm）含膏量 14g，含利多卡因 700mg 4、注册分类：化学药品 3 类 5、申请事项：药品注册（境内生产） 6、证书编号：2025S01264 湖南九典制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 ...

Group 1 - The stock price of Jiutian Pharmaceutical (300705) closed at 16.08 yuan on May 20, 2025, with an increase of 2.03% and a trading volume of 140,200 shares, resulting in a transaction amount of 225 million yuan [1] - The company has a comprehensive layout in the fields of chemical drug formulations, raw materials, pharmaceutical excipients, traditional Chinese medicine, and health products [1] - On May 20, the net inflow of main funds was 11.79 million yuan, while the net outflow of speculative funds was 18.14 million yuan, and the net inflow of retail investors was 6.35 million yuan [3] Group 2 - Jiutian Pharmaceutical announced an adjustment of the conversion price for the bond "Jiutian Convertible Bond 02" from 15.33 yuan/share to 15.02 yuan/share, effective from May 26, 2025 [2][3] - The company plans to distribute a cash dividend of 3.129649 yuan per 10 shares to all shareholders, with a per-share cash dividend ratio of 0.3098112 yuan/share after the distribution [2]

Group 1 - The company announced an adjustment to the conversion price of its convertible bonds "九典转 02" due to its 2024 profit distribution plan [1][2] - The adjusted conversion price is set at 15.02 yuan per share, effective from May 26, 2025 [3] - The profit distribution plan includes a cash dividend of 0.3098112 yuan per share, with no stock dividends or capital increases [2][3] Group 2 - The company will follow specific formulas for adjusting the conversion price based on changes in share capital, including stock dividends, capital increases, and cash dividends [1][2] - The adjustment will be disclosed in a public announcement, detailing the adjustment date and method [2]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于九典转 02 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 增发新股或配股：P1=（P0+A×k）/（1+k）； 1、债券代码：123223；债券简称：九典转 02 2、调整前转股价格：人民币 15.33 元/股 3、调整后转股价格：人民币 15.02 元/股 4、转股价格调整生效日期：2025 年 5 月 26 日 上述两项同时进行：P1=（P0+A×k）/（1+n+k）； 派送现金股利：P1=P0-D； 上述三项同时进行：P1=（P0-D+A×k）/（1+n+k）。 其中：P1 为调整后转股价，P0 为调整前转股价，n 为送股或转增股本率，A 为增发新股价或配股价，k 为增发新股或配股率，D 为每股派送现金股利。 当公司出现上述股份和/或股东权益变化情况时，将依 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、湖南九典制药股份有限公司（以下简称"公司"）通过回购专户持有的 公司股份5,000,000股，不参与本次权益分派。因此，本次权益分派以总股本扣 除公司回购专户中已回购股份后的总股本491,198,771股为基数，向全体股东每 10股派发现金股利人民币3.129649元（含税）。 2、本次权益分派实施后，按公司总股本折算每股现金分红比例计算如下： 公司总股本折算每股现金红利=本次实际现金分红总额÷股权登记日的总股本= （股权登记日的总股本-回购专户中的股份）×每股分红金额÷股权登记日的总 股本=491,198,771×3.129649÷10÷496,198,771=0.3098112元/股，每10股现金 红利为3.098112元。 3、2024年度权益分派 ...

特别提示： 湖南九典制药股份有限公司（以下简称"公司"）于2025年5月15日召开2024 年度股东会，审议通过了《关于2024年度利润分配预案的议案》。近日，公司将 根据相关决议实施2024年度权益分派。 特此公告。 湖南九典制药股份有限公司董事会 湖南九典制药股份有限公司 关于实施 2024 年度权益分派期间九典转 02 暂停转股的公告 2025 年 5 月 16 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》相关规定，自2025年5月19日至2024年度权益分派股权登记日期间 九典转02暂停转股，自2024年度权益分派股权登记日后的第一个交易日起九典转 02恢复转股。在上述暂停转股期间，九典转02正常交易，敬请各位债券持有人留 意。 1、债券代码：123223 债券简称：九典转02 ...

Group 1: Sales Performance - The sales of Loxoprofen Sodium Gel Patch are normal, with rapid growth in sales volume achieved through "price for volume" strategy in the hospital market [2] - The company is increasing investment in the outpatient market, promoting rapid growth in outpatient sales revenue through "Jiuyue" brand building and channel penetration [2] Group 2: Product Development - Currently, five external preparations are on the market: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Ketorolac Gel, Lidocaine Double Cardine Cream, and Anti-inflammatory Pain Relief Patch [3] - Expected approvals for 2025 include Lidocaine Gel Patch, Indomethacin Gel Patch, Flurbiprofen Gel Patch, and Loxoprofen Sodium Patch [3] - Future approvals in 2026 are anticipated for Ketoprofen Patch, Flurbiprofen Patch, Clobetasol Soft Ointment, and Diclofenac Diethylamine Emulsion [3] Group 3: Mergers and Acquisitions Strategy - The company will consider multiple directions for mergers and acquisitions, focusing on targets that align with its development strategy, enhance the industrial chain, improve technology, and enrich the product pipeline [4] Group 4: Market Adaptation - Overseas transdermal drug products are widely used for pain relief, hormone replacement, cardiovascular, and neurological diseases, including Fentanyl Patch, Lidocaine Gel Patch, Nitroglycerin Patch, and others [5] Group 5: Production Capacity - The company currently has sufficient production capacity to meet existing demand and has reserved workshop space for future needs [6] - Short-term capacity can be increased by adding new production line equipment, while long-term plans will be developed based on operational needs [6] Group 6: Future Strategic Focus - The company aims to expand sales channels, particularly increasing penetration in the outpatient market and enhancing brand influence [7] - There will be a continued emphasis on R&D to develop new products and enrich the product line [8] - The company will optimize production processes and strengthen cost control mechanisms to ensure efficient operations and good returns for shareholders [8]